These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38146645)

  • 21. [Comparison of three commercial photosensitizers for efficiency of inducing immunogenic cell death in anti-tumor immunotherapy].
    Lin X; Mao D; Bai R
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1791-1798. PubMed ID: 36651246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
    Okimoto T; Kotani H; Iida Y; Koyanagi A; Tanino R; Tsubata Y; Isobe T; Harada M
    Cancer Sci; 2020 Jun; 111(6):1910-1920. PubMed ID: 32232903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer.
    Li S; Wang S; Zhang A; Luo L; Song J; Wei G; Fang Z
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.
    Sakakibara K; Sato T; Kufe DW; VonHoff DD; Kawabe T
    Oncotarget; 2017 Oct; 8(45):78277-78288. PubMed ID: 29108228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
    Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
    Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells.
    Xue X; Ye G; Zhang L; Zhu X; Liu Q; Rui G; Geng G; Lin Y; Chen X
    Int Immunopharmacol; 2024 Mar; 130():111747. PubMed ID: 38442576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors.
    Yerragopu AK; Vellapandian C
    J Biochem Mol Toxicol; 2023 May; 37(5):e23327. PubMed ID: 36807623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1/PD-L1 treatment in a lung cancer model.
    Yu J; Zhang Q; Li J; Si Z; Guo Y; Xu X; Wu K
    J Investig Med; 2022 Mar; 70(3):792-799. PubMed ID: 34872935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
    Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
    Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
    Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
    Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.
    Yamazaki T; Buqué A; Ames TD; Galluzzi L
    Oncoimmunology; 2020; 9(1):1721810. PubMed ID: 32117585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
    Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
    Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer.
    Chen MC; Hung MY; Pan CM; Huang SW; Jan CI; Li YH; Chiu SC; Cho DY
    Cancer Sci; 2023 Jul; 114(7):2761-2773. PubMed ID: 37017116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8
    Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B
    Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy.
    Nakamura M; Magara T; Yoshimitsu M; Kano S; Kato H; Yokota K; Okuda K; Morita A
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39089738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.